(IDYA) IDEAYA Biosciences, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IDYA) IDEAYA Biosciences, Inc. Complete Analysis Pack
Unlock the Full Ansoff Matrix for Deeper Strategic Insight
This IDEAYA Biosciences, Inc. Ansoff Matrix Analysis shows practical growth options across market penetration, market development, product development, and diversification to inform strategy, investing, or planning. The page already includes a real preview/sample of the analysis so you can judge the format and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix.
Market Penetration
IDE397 Phase I MTAP-deleted solid tumor enrollment
IDE397’s Phase I solid-tumor program targets the MTAP-deleted subset, which appears in about 10% to 15% of cancers, so the Ansoff move is deeper penetration inside an existing precision-oncology pool. More site activation and faster screening can lift enrollment in this same biomarker-defined segment and help IDEAYA Biosciences, Inc. capture a bigger share of eligible patients without changing the core indication.
IDE196 Phase I/II GNAQ/GNA11-mutant cancer reach
IDE196 is in Phase I/II for GNAQ/GNA11-mutant cancers, with the main fit in metastatic uveal melanoma, where GNAQ/GNA11 alterations drive about 80% to 90% of cases. This is market penetration, not new-market play: IDEAYA Biosciences, Inc. is deepening use in the same mutation-defined niche. The upside comes from more trial sites and, if data hold, a larger share of a small but highly targeted patient pool.
Biomarker-led patient selection
IDEAYA Biosciences, Inc. uses biomarker-led patient selection to narrow trial and treatment pools to the exact molecular subsets it can target. In current oncology markets, this is a direct penetration lever: MTAP-deleted tumors are about 10% to 15% of solid tumors, so tighter screening lifts the hit rate from broad tumor populations into addressable patients. That improves trial efficiency and commercial conversion without changing the core market.
Pfizer-backed development in uveal melanoma and melanoma
IDEAYA Biosciences, Inc.'s Pfizer-backed Phase I/II work strengthens reach in metastatic uveal melanoma, skin melanoma, and other solid tumors. Uveal melanoma is rare, with about 2,000 U.S. cases a year, while skin melanoma exceeds 100,000 annual U.S. cases, so even small share gains matter. The Pfizer supply and development deal can speed trial scale and deepen IDEAYA’s grip in these existing oncology markets.
- Phase I/II Pfizer support
- Targets existing oncology segments
- Uveal melanoma: ~2,000 U.S. cases
- Skin melanoma: 100,000+ U.S. cases
Synthetic lethality focus in precision oncology
IDEAYA Biosciences, Inc. stays tightly focused on synthetic lethality, so its market penetration grows by deepening one precision-oncology niche instead of chasing broad tumor classes. That model helps it reuse the same investigators, biomarker tests, and trial sites across programs, which lowers friction and can speed enrollment in a crowded 2025-2026 oncology trial base. In 2025, that focus also mattered because IDEAYA had multiple synthetic-lethality programs in the clinic, reinforcing specialist credibility with the same prescriber and research network.
- Same niche, same investigators, same biomarker workflow.
- Repeat use can improve trial speed and trust.
- Focused pipeline supports clearer partner talks.
IDEAYA Targets Smaller, Deeper Biomarker-Cancer Pools
IDEAYA Biosciences, Inc. is using market penetration by pushing the same biomarker-defined oncology pools harder, not entering new ones. IDE397 targets MTAP-deleted tumors, about 10%-15% of solid cancers, and IDE196 targets GNAQ/GNA11-mutant cancers, which drive about 80%-90% of metastatic uveal melanoma.
| Program | 2025/2026 | Pool |
|---|---|---|
| IDE397 | Phase I | 10%-15% |
| IDE196 | Phase I/II | 80%-90% |
What is included in the product
Detailed Word Document
Outlines IDEAYA Biosciences, Inc.’s growth options across existing and new products and markets
Editable Excel File
Provides a quick Ansoff Matrix view of IDEAYA Biosciences’ growth options for faster strategy alignment.
Reference Sources
Cites authoritative filings, trial data, investor materials, and industry reports to fast-verify IDEAYA’s Ansoff growth assumptions.
Market Development
IDE397 expansion across MTAP-deleted solid tumors
IDE397 is already in MTAP-deleted solid tumors, so market development means using the same biomarker across more tumor types without changing the drug’s core biology. MTAP deletion is found in about 10% to 15% of solid tumors, which widens the addressable patient pool. IDEAYA Biosciences, Inc. can scale reach from one niche to a broader biomarker-defined market.
IDE196 reach into broader genetically defined cancers
IDE196 is a market-development play because it turns one molecule into a broader, mutation-defined cancer platform. GNAQ or GNA11 mutations drive about 80% of uveal melanoma, and expanding into other mutation-positive tumors can open a new patient pool beyond the core niche. IDEAYA reported about $841 million in cash and investments at 2025 year-end, supporting this expansion.
Pfizer collaboration for metastatic uveal melanoma, skin melanoma, and other solid tumors
Pfizer collaboration is a Market Development move: one alliance now spans 3 tumor groups—metastatic uveal melanoma, skin melanoma, and other solid tumors—so IDEAYA Biosciences, Inc. can push the same portfolio into new clinical segments. That broadens addressable use without rebuilding the asset base, which lowers launch risk and can lift peak sales from one program. In 2025, IDEAYA reported continued pipeline expansion across these settings.
UK research linkage through Cancer Research UK and the University of Manchester
IDEAYA Biosciences, Inc.’s PARG inhibitor work with Cancer Research UK and the University of Manchester gives it a new external R&D base and wider access to UK oncology expertise. The UK has a 67.7 million population and a deep cancer-research network, so this partnership can broaden discovery reach beyond South San Francisco.
- New UK R&D access
- Broader oncology reach
- Stronger partner-led research
Strategic alliance with GlaxoSmithKline plc
IDEAYA Biosciences, Inc.'s alliance with GlaxoSmithKline plc widens its reach through GSK’s global development and commercial network, making this a clear market-development move. GSK reported £31.4 billion in 2024 sales, showing the scale behind that channel. For IDEAYA, the partnership can speed clinical access and de-risk expansion without building a bigger field force.
- Uses GSK’s global trial network
- Expands reach beyond IDEAYA alone
- Lowers go-to-market build costs
IDEAYA Expands Biomarker Plays With Strong Cash Backing
IDEAYA Biosciences, Inc. is using market development to widen each biomarker play into more tumors without changing the core drug. IDE397 targets MTAP-deleted solid tumors, a pool seen in about 10% to 15% of solid tumors, while IDE196 extends into other GNAQ or GNA11-driven cancers, which cause about 80% of uveal melanoma. Cash and investments were about $841 million at 2025 year-end.
| Program | Market move | Key data |
|---|---|---|
| IDE397 | Broader MTAP use | 10% to 15% of solid tumors |
| IDE196 | More mutation-defined cancers | About 80% of uveal melanoma |
| Balance sheet | Supports expansion | $841 million at 2025 year-end |
Full Version Awaits
IDEAYA Biosciences, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. It maps IDEAYA Biosciences’ growth options across market penetration, product development, market development, and diversification with actionable insights and risk notes. The full, editable version is available after checkout.
Product Development
IDE397 MAT2A inhibitor progression
IDE397 is IDEAYA Biosciences’ MAT2A inhibitor, so its progression is a new product move inside the same precision-oncology niche. The program is tightly biomarker-led for MTAP-deleted tumors, a loss seen in about 10%-15% of solid tumors, which narrows the target pool but improves patient selection. That keeps the asset aligned with a focused, high-value oncology strategy.
IDE196 PKC inhibitor progression
IDE196, a protein kinase C inhibitor, is a product expansion move for IDEAYA Biosciences in genetically defined cancers. Its Phase I/II program targets GNAQ and GNA11-mutant tumors, including uveal melanoma, aiming at a clearly segmented oncology niche. This builds a differentiated product around a biomarker-led approach, with IDEAYA reporting 1Q 2025 cash and investments of $788.5 million.
PARG inhibitor program
IDEAYA Biosciences, Inc.'s earlier-stage PARG inhibitor program adds a new small-molecule oncology candidate and fits Ansoff's product development path: new products for existing cancer markets. The biomarker-led design targets tumors with specific genetic or molecular drivers, which can sharpen patient selection and raise response odds. In a pipeline with 1 new mechanism, this helps widen IDEAYA Biosciences, Inc.'s precision-oncology reach without changing its core focus.
Pol Theta inhibitor program
IDEAYA’s Pol theta inhibitor program targets BRCA and other homologous recombination deficiency tumors, adding a new DNA-repair branch to its synthetic lethality platform. BRCA1/2 mutations appear in about 5%-10% of breast cancers and 15%-20% of ovarian cancers, so the addressable pool is real and tied to validated biology.
- Distinct DNA-repair expansion
- Fits synthetic lethality strategy
- Targets BRCA/HRD cancers
WRN inhibitor program
IDEAYA Biosciences, Inc. is extending its product development strategy with a WRN inhibitor for MSI-H tumors, a biomarker-selected cancer group. MSI-H shows up in about 3% to 5% of solid tumors, so the program targets a defined niche rather than a broad market.
- New precision-oncology product
- Targets MSI-H biomarker group
- Deepens IDEAYA's pipeline
This fits Ansoff product development: same oncology focus, new pipeline asset. It can broaden IDEAYA Biosciences, Inc.'s future mix beyond one program set and add another shot at a high-value, genomically defined cancer segment.
IDEAYA’s Precision-Oncology Pipeline Expands With Strong Cash Support
IDEAYA Biosciences, Inc.’s product development is classic Ansoff: new precision-oncology drugs for the same cancer market. In 1Q 2025, cash and investments were $788.5 million, which supports multiple mid-stage shots. IDE397, IDE196, PARG, Pol theta, and WRN all widen the pipeline around biomarker-selected tumors.
| Program | Fit | 2025 data |
|---|---|---|
| IDE397 | New product | MTAP-deleted tumors |
| IDE196 | Expansion | 1Q 2025 cash $788.5M |
| WRN | New niche | MSI-H tumors |
Diversification
PARG inhibitor research with Cancer Research UK and Manchester
IDEAYA Biosciences, Inc. is advancing its PARG inhibitor with Cancer Research UK and the University of Manchester, linking one new oncology asset to a new external research network. In Ansoff terms, this is diversification: a new product built through a partnership-led model, not a simple line extension. It also broadens IDEAYA’s target pool beyond its core programs, adding 1 more early-stage research route.
Multiple synthetic lethality targets beyond the lead assets
IDEAYA Biosciences, Inc. is not tied only to IDE397 and IDE196; it also advances PARG, Pol Theta, and WRN programs. That gives it at least three more synthetic-lethality shots across distinct target classes and biomarker-linked tumor markets. The spread lowers single-asset risk and broadens the upside if one program misses.
Pharma alliance model with Pfizer
IDEAYA’s Pfizer alliance shifts Phase I/II clinical development and supply to a partner, instead of an internal-only path. That diversifies execution risk across 2 companies and can speed oncology asset work. For IDEAYA, it also broadens development capacity without building every clinical and manufacturing step in-house.
Strategic alliance with GlaxoSmithKline plc
The GlaxoSmithKline plc alliance gives IDEAYA Biosciences, Inc. a second major pharma development channel, alongside Pfizer, so the company can spread future programs across 2 large partners instead of 1. That lowers single-partner dependence and supports diversification in Ansoff Matrix terms, because IDEAYA can use the same science platform in a broader execution model.
- 2 major pharma partners: GSK and Pfizer
- Less reliance on one deal path
- More options for future program launches
Broad biomarker portfolio across MTAP, GNAQ/GNA11, BRCA/HRD, and MSI-H
IDEAYA Biosciences, Inc. is diversifying across four biomarker-led markets: MTAP deletions, GNAQ/GNA11 mutations, BRCA/HRD, and MSI-H. That is a clear Ansoff diversification play, because it expands into new molecular segments and multiple product classes, not just one disease niche. The mix also reduces dependence on any single tumor biology.
- Four biomarker groups
- New molecular markets
- Multiple product classes
- Lower single-target risk
IDEAYA Diversifies Beyond Core with 2 Partners and 4 Biomarker Bets
IDEAYA Biosciences, Inc. is using diversification in Ansoff terms by pushing beyond its core assets into partnered new programs like PARG, adding a second pharma channel with Pfizer and GSK. It also spans four biomarker markets: MTAP, GNAQ/GNA11, BRCA/HRD, and MSI-H. That spreads execution and biology risk across 2 major partners and 4 target groups.
| Driver | Count |
|---|---|
| Major pharma partners | 2 |
| Biomarker groups | 4 |
| New external research route | 1 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.